Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Current renal cell carcinoma (RCC) therapies include tyrosine kinase inhibitors, immune checkpoint inhibitors, and mTOR inhibitors.
• Advances in understanding RCC biology have spurred development of novel agents targeting hypoxia-inducible factor 2 and MET pathways.
• Exploration continues into targeting immune pathways beyond PD-1/PD-L1 and CTLA-4.

Purpose of the Study:

• To review key targets in clinical evaluation for RCC.
• To examine the evolution of drug development in RCC over the past two decades.
• To forecast future directions in RCC therapeutic strategies.

Main Methods:

• Literature review of approved therapies and ongoing clinical trials in RCC.
• Analysis of biological insights driving new drug development.
• Synthesis of historical trends and future projections in RCC treatment.

Main Results:

• Several new therapies have been approved in the last decade, expanding treatment options.
• Drug development is increasingly focused on combination therapies and risk-adapted treatment approaches.
• Novel targets like HIF-2 and MET are under investigation, alongside other immune pathways.

Conclusions:

• Despite progress, there is a critical need for novel therapeutic targets and an expanded armamentarium for both clear cell and non-clear cell RCC.
• Future drug development should prioritize innovative targets and combination strategies.
• The review provides insights into the evolving landscape of RCC therapeutics.